Get email updates from SABCSMeetingNews.org
Subscribe to get regular news updates from SABCS.org and SABCS Meeting News.
The final session of SABCS 2021 highlighted some of the most important breast cancer results from the meeting and put the findings into context for day-to-day clinical practice.
A panel of experts discussed some of the latest advances in early and advanced breast cancer, basic science, and translational research during the special session Year in Review on Friday.
In her plenary lecture on Friday, medical oncologist Lisa A. Carey, MD, ScM, discussed triple negative breast cancer, including advancements in treatment options and implications for population health.
During the plenary lecture on Thursday, Mitchell Dowsett, PhD, FMedSci, looked at genetic profiling from early research to clinical utility and addressed clinically critical questions that have yet to be answered.
Friday’s General Session included two studies into race as a factor in the incidence, severity, and treatment outcomes of breast cancer.
Fabrice André, MD, PhD, received this year’s AACR Outstanding Investigator Award for Breast Cancer Research for his work helping to establish the concept of using real-time, high-throughput genomic analysis of cancer biopsies to identify potential therapeutic targets.
Lori Wilson, MD, and Charles Perou, PhD, gave keynote presentations during a special session focused on advancing health equity through building trust and improving access to care and clinical trials.
Thursday’s General Session included findings from a study looking at fulvestrant plus palbociclib for HR+ breast cancer and results of a study of pyrotinib plus capecitabine for previously treated HER2+ metastatic breast cancer.
Helen M. Piwnica-Worms, PhD, discussed her journey from basic research to translational trials during the 2021 AACR Distinguished Lectureship in Breast Cancer Research on Thursday.
During a debate this morning, Charlotte Coles, MBChB, PhD, will present the “Pro” argument, and Julia White, MD, will present the “Con” argument on the adoption of a new schedule for whole breast radiotherapy.